Related Experiment Videos
Epidemiology of hyperuricemia and gout
Insights
Gout is increasingly common, with new risk factors like metabolic syndrome and longer lifespans. This review covers updated epidemiology and management challenges for this ancient disease.
Area of Science:
- Rheumatology
- Epidemiology
- Cardiovascular Medicine
Background:
- Gout prevalence is rising, extending beyond traditional risk factors.
- New risk factors include metabolic syndrome, aging populations, and certain medications.
- Atypical gout presentations in the elderly can be misdiagnosed.
Purpose of the Study:
- To review current epidemiologic data on gout.
- To highlight emerging risk factors and their associations.
- To discuss challenges in gout pharmacologic management.
Main Methods:
- Literature review of recent epidemiologic studies on gout.
- Analysis of new risk factors and their prevalence.
- Examination of quality control issues in gout treatment.
Main Results:
- Gout risk is associated with increased longevity and metabolic syndrome components.
- Medications like diuretics and cyclosporine are linked to gout.
- Hyperuricemia is recognized as a modifiable cardiovascular risk factor.
Conclusions:
- Gout epidemiology is evolving with new risk factors and patient demographics.
- Effective management requires addressing these new factors and improving treatment quality.
- Further research is needed to understand gout's cardiovascular implications.
Abstract:
Gout is an increasingly common medical problem. The traditional risk factors of male sex and high red meat or alcohol consumption have been joined by a wave of newer risk factors, such as increased longevity, the metabolic syndrome (hypertension, diabetes, dyslipidemia, truncal obesity, increased cardiovascular disease risk), use of diuretics, low-dose aspirin, or cyclosporine, and end-stage renal disease. Atypical presentations of gout in the elderly can mimic osteoarthritis and rheumatoid arthritis. There is a resurgence of interest in hyperuricemia as an independent and potentially modifiable cardiovascular risk factor. The pharmacologic management of gout in general practice suffers from a number of quality-control issues. This article reviews these and other new epidemiologic data on this ancient disease.
Related Concept Videos
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Nursing Assessment of the Genitourinary System I: Health History
Urinary Tract Infection II: Pathophysiology
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Calculi I: Introduction